Archives of the Turkish Society of Cardiology
New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) Where do we stand?: An expert consensus view using the Delphi method [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2021; 49(5): 345-352 | DOI: 10.5543/tkda.2021.40652

New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) Where do we stand?: An expert consensus view using the Delphi method

Mustafa Arıcı1, Tevfik Ecder2, İzzet Erdinler3, Ercan Ok4, Özlem Arıcan Özlük5, Uğur Önsel Türk6, Emin Alioğlu6
1Department of Nephrology, Hacettepe University School of Medicine, Ankara, Turkey
2Department of Nephrology, Demiroğlu Bilim University School of Medicine, İstanbul, Turkey
3Department of Cardiology, Memorial Ataşehir Hospital, İstanbul, Turkey
4Department of Nephrology, Ege University School of Medicine, İzmir, Turkey
5Department of Cardiology, Yüksek İhtisas Training and Research Hospital, Bursa, Turkey
6Department of Cardiology, İzmir Economy University School of Medicine, İzmir, Turkey

Keywords: Atrial fibrillation, non-vitamin K antagonist anticoagulants (NOACs), end-stage renal disease

How to cite this article
Mustafa Arıcı, Tevfik Ecder, İzzet Erdinler, Ercan Ok, Özlem Arıcan Özlük, Uğur Önsel Türk, Emin Alioğlu. New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) Where do we stand?: An expert consensus view using the Delphi method. Turk Kardiyol Dern Ars. 2021; 49(5): 345-352

Corresponding Author: Emin Alioğlu, Türkiye
© Copyright 2021 Archives of the Turkish Society of Cardiology
LookUs & Online Makale